Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with unresectable, locally recurrent or metastatic breast cancer after prior anthracycline-based adjuvant chemotherapy
Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with unresectable, locally recurrent or metastatic breast cancer after prior anthracycline-based adjuvant chemotherapy
A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer (Victoria)
Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with unresectable, locally recurrent or metastatic breast cancer after prior anthracycline-based adjuvant chemotherapy
Status
Status :
Completed
Type of study
Phase III
Min. Age
18
Years old
Max. Age
75
Years old
Gender
Female
Therapeutic area :
Oncology
Disease :
Breast cancer
Study medication :
Vinflunine (Javlor®)
Phase :
Phase III
Start Date :
27 June 2006
End date :
25 February 2015
Study ID :
L00070 IN 303 B0
EudraCT/CTIS number :
2006-001139-23
CT.gov Number :
NCT02054338
Send by email